Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors
暂无分享,去创建一个
Chitra Subramanian | C. Rock | C. Subramanian | Joshua B Parsons | Matthew W. Frank | Charles O Rock | Matthew W Frank | Panatda Saenkham | Panatda Saenkham | Joshua B. Parsons
[1] N. Oppenheimer,et al. Structure and mechanism , 1989 .
[2] Won-Gon Kim,et al. Aquastatin A, a new inhibitor of enoyl-acyl carrier protein reductase from Sporothrix sp. FN611. , 2009, Biological & pharmaceutical bulletin.
[3] C. Walsh,et al. Andrimid producers encode an acetyl-CoA carboxyltransferase subunit resistant to the action of the antibiotic , 2008, Proceedings of the National Academy of Sciences.
[4] D. de Mendoza,et al. A malonyl‐CoA‐dependent switch in the bacterial response to a dysfunction of lipid metabolism , 2008, Molecular microbiology.
[5] C. Raetz,et al. Lipid A modification systems in gram-negative bacteria. , 2007, Annual review of biochemistry.
[6] Yasutaro Fujita,et al. Regulation of fatty acid metabolism in bacteria , 2007, Molecular microbiology.
[7] C. Rock,et al. Thiolactomycin resistance in Escherichia coli is associated with the multidrug resistance efflux pump encoded by emrAB , 1993, Journal of bacteriology.
[8] S Omura,et al. Inhibition of fatty acid synthesis by the antibiotic cerulenin. Specific inactivation of beta-ketoacyl-acyl carrier protein synthetase. , 1973, Biochimica et biophysica acta.
[9] Mi-Jin Sohn,et al. Macrolactin S (I), a New Antibacterial Agent with FabG-Inhibitory Activity from Bacillus sp. AT28. , 2009 .
[10] D. Henner,et al. Construction of a vector for cloning promoters in Bacillus subtilis. , 1983, Gene.
[11] G. Volckaert,et al. The kalimantacin/batumin biosynthesis operon encodes a self-resistance isoform of the FabI bacterial target. , 2010, Chemistry & biology.
[12] N. Kaplan,et al. AFN-1252, a FabI Inhibitor, Demonstrates a Staphylococcus-Specific Spectrum of Activity , 2009, Antimicrobial Agents and Chemotherapy.
[13] R. Heath,et al. Inhibition of -Ketoacyl-Acyl Carrier Protein Synthase III (FabH) by Acyl-Acyl Carrier Protein in Escherichia coli(*) , 1996, The Journal of Biological Chemistry.
[14] H. Okazaki,et al. Thiolactomycin, a new antibiotic. III. In vitro antibacterial activity. , 1982, The Journal of antibiotics.
[15] C. Rock,et al. Acetoacetyl-acyl carrier protein synthase, a potential regulator of fatty acid biosynthesis in bacteria. , 1987, The Journal of biological chemistry.
[16] C. Rock,et al. Acyl-phosphates initiate membrane phospholipid synthesis in Gram-positive pathogens. , 2006, Molecular cell.
[17] P. Tonge,et al. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway. , 2008, Accounts of chemical research.
[18] J. Cronan,et al. The soluble acyl-acyl carrier protein synthetase of Vibrio harveyi B392 is a member of the medium chain acyl-CoA synthetase family. , 2006, Biochemistry.
[19] S. Ōmura. The antibiotic cerulenin, a novel tool for biochemistry as an inhibitor of fatty acid synthesis. , 1976, Bacteriological reviews.
[20] C. Walsh. Opinion — anti-infectives: Where will new antibiotics come from? , 2003, Nature Reviews Microbiology.
[21] Koen Andries,et al. Essentiality of FASII pathway for Staphylococcus aureus , 2010, Nature.
[22] B. Staels,et al. Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens , 2009, Nature.
[23] J. W. Campbell,et al. Expression of Vibrio harveyi acyl-ACP synthetase allows efficient entry of exogenous fatty acids into the Escherichia coli fatty acid and lipid A synthetic pathways. , 2010, Biochemistry.
[24] B. Staels,et al. Brinster et al. reply , 2010, Nature.
[25] R. Heath,et al. Broad Spectrum Antimicrobial Biocides Target the FabI Component of Fatty Acid Synthesis* , 1998, The Journal of Biological Chemistry.
[26] Y. Harada,et al. Thiolactomycin, a new antibiotic. IV. Biological properties and chemotherapeutic activity in mice. , 1982, The Journal of antibiotics.
[27] J. Cronan,et al. Inhibition of Escherichia coliAcetyl Coenzyme A Carboxylase by Acyl-Acyl Carrier Protein , 2001, Journal of bacteriology.
[28] T. Lampe,et al. Novel Bacterial Acetyl Coenzyme A Carboxylase Inhibitors with Antibiotic Efficacy In Vivo , 2006, Antimicrobial Agents and Chemotherapy.
[29] P. Tonge,et al. Inhibitors of Fabl, an Enzyme Drug Target in the Bacterial Fatty Acid Biosynthesis Pathway , 2008 .
[30] Xiayang Qiu,et al. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK. , 2003, Journal of medicinal chemistry.
[31] F. Neidhardt,et al. Escherichia Coli and Salmonella: Typhimurium Cellular and Molecular Biology , 1987 .
[32] S. Levy,et al. Triclosan targets lipid synthesis , 1998, Nature.
[33] Alejandro Buschiazzo,et al. Structural basis of lipid biosynthesis regulation in Gram‐positive bacteria , 2006, The EMBO journal.
[34] Young-Soo Hong,et al. Cephalochromin, a FabI-directed antibacterial of microbial origin. , 2007, Biochemical and biophysical research communications.
[35] Martha S. Head,et al. Discovery of a Novel and Potent Class of FabI-Directed Antibacterial Agents , 2002, Antimicrobial Agents and Chemotherapy.
[36] Henry F. Chambers,et al. Waves of resistance: Staphylococcus aureus in the antibiotic era , 2009, Nature Reviews Microbiology.
[37] R. Altenbern,et al. Cerulenin-Inhibited Cells of Staphylococcus aureus Resume Growth When Supplemented with Either a Saturated or an Unsaturated Fatty Acid , 1977, Antimicrobial Agents and Chemotherapy.
[38] R. Heath,et al. Enoyl-Acyl Carrier Protein Reductase (fabI) Plays a Determinant Role in Completing Cycles of Fatty Acid Elongation in Escherichia coli(*) , 1995, The Journal of Biological Chemistry.
[39] H. Okazaki,et al. THIOLACTOMYCIN, A NEW ANTIBIOTIC , 1982 .
[40] Xiayang Qiu,et al. Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI). , 2002, Journal of medicinal chemistry.
[41] R. Heath,et al. Inhibition of β-Ketoacyl-Acyl Carrier Protein Synthases by Thiolactomycin and Cerulenin , 2001, The Journal of Biological Chemistry.
[42] J. Sacchettini,et al. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis , 1995, Science.
[43] C. Rock,et al. Acyl-Acyl Carrier Protein Regulates Transcription of Fatty Acid Biosynthetic Genes via the FabT Repressor in Streptococcus pneumoniae* , 2009, The Journal of Biological Chemistry.
[44] Jun Wang,et al. Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties , 2007, Proceedings of the National Academy of Sciences.
[45] R. Heath,et al. Characterization of Streptococcus pneumoniae enoyl-(acyl-carrier protein) reductase (FabK). , 2003, The Biochemical journal.
[46] Alla Karnovsky,et al. A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore , 2009, Proceedings of the National Academy of Sciences.
[47] Jun Wang,et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties , 2006, Nature.